The TB Europe Coalition
has published a report summarizing the findings of a 2024 community-led
monitoring (CLM) initiative that assessed the procurement processes for shorter
TB treatment regimens in four Eastern Europe and Central Asia (EECA) countries
over the 2022–2024 period - https://tbcoalition.eu/resource/files/2025/06/report-on-the-clm-of-shorter-tb-treatment-regimens_eng.pdf
As a mechanism ensuring independent oversight and community engagement, the CLM focused on evaluating the current status of access to and availability of the latest shorter TB treatment regimens, as well as identifying existing gaps in Kyrgyzstan, Moldova, Tajikistan, and Ukraine.
The assessment covered national legislation and international procurement mechanisms and projects related to TB drugs for shorter treatment regimens. This included funding and procurement volumes, international nonproprietary names, quantities, prices, and manufacturers. Interviews were also conducted with specialists from the national TB programs’ pharmaceutical and statistical units.
Additionally, the analysis included:
- Lists of medicines eligible for public procurement and drug registration procedures (including regulations for importation and distribution without registration);
- Comprehensive lists of shorter TB treatment regimens procured through national budgets and international procurement mechanisms;
- Data on the number of people in need of shorter TB treatment regimens (disaggregated by TB type), and the actual number of patients receiving such regimens.
Based on the CLM results, a set of recommendations was developed to support improvements in shorter TB treatment regimens procurement systems across all four countries involved.
The report was prepared with financial support from the Stop TB Partnership under Round 12 of the Challenge Facility for Civil Society (CFCS).
